Abstract
Since decades the urokinase plasminogen activator (uPA) system has been associated with the invasion of malignant cells. The receptor of urokinase (uPAR) is one of the key players in this proteolytic cascade, because it focuses uPAs proteolytic activity to the cell surface and in addition functions as a signaling receptor. uPAR is highly expressed in virtually all human cancers, suggesting possible clinical applications as diagnostic marker, predictive tool of survival or clinical response, and as a target for therapy and imaging. This review summarizes the possibilities of uPAR in clinical applications for cancer patients.
Keywords: uPAR, diagnosis, prognosis, imaging, targeting, therapy, exosomes, tumor, rheumatoid arthritis, AIDS, ELISA, nano-particles, biopsies, Image-guided surgery (IGS), renal threshold
Current Pharmaceutical Design
Title: Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients
Volume: 17 Issue: 19
Author(s): Martin C. Boonstra, Hein W. Verspaget, Sjam Ganesh, Frank J.G.M. Kubben, Alexander L. Vahrmeijer, Cornelis J.H. van de Velde, Peter J.K. Kuppen, Paul H.A. Quax and Cornelis F.M. Sier
Affiliation:
Keywords: uPAR, diagnosis, prognosis, imaging, targeting, therapy, exosomes, tumor, rheumatoid arthritis, AIDS, ELISA, nano-particles, biopsies, Image-guided surgery (IGS), renal threshold
Abstract: Since decades the urokinase plasminogen activator (uPA) system has been associated with the invasion of malignant cells. The receptor of urokinase (uPAR) is one of the key players in this proteolytic cascade, because it focuses uPAs proteolytic activity to the cell surface and in addition functions as a signaling receptor. uPAR is highly expressed in virtually all human cancers, suggesting possible clinical applications as diagnostic marker, predictive tool of survival or clinical response, and as a target for therapy and imaging. This review summarizes the possibilities of uPAR in clinical applications for cancer patients.
Export Options
About this article
Cite this article as:
C. Boonstra Martin, W. Verspaget Hein, Ganesh Sjam, J.G.M. Kubben Frank, L. Vahrmeijer Alexander, J.H. van de Velde Cornelis, J.K. Kuppen Peter, H.A. Quax Paul and F.M. Sier Cornelis, Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients, Current Pharmaceutical Design 2011; 17 (19) . https://dx.doi.org/10.2174/138161211796718233
DOI https://dx.doi.org/10.2174/138161211796718233 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HIF Prolyl-4-hydroxylase Interacting Proteins: Consequences for Drug Targeting
Current Pharmaceutical Design Colon Cancer Therapy: Recent Developments in Nanomedicine to Improve the Efficacy of Conventional Chemotherapeutic Drugs
Anti-Cancer Agents in Medicinal Chemistry Regulation and Function of DNA and Histone Methylations
Current Pharmaceutical Design Microbial Polysaccharides and their Derivatives as Current and Prospective Pharmaceuticals
Current Pharmaceutical Design Hormone Responsive Breast Cancer and BRCA1 Mutation: Mechanism, Regulation and Iron-mediated Effects
Current Pharmaceutical Biotechnology Inhibition of the Tissue Factor Coagulation Pathway
Current Vascular Pharmacology Stem Cell Differentiation Stage Factors and their Role in Triggering Symmetry Breaking Processes during Cancer Development: A Quantum Field Theory Model for Reprogramming Cancer Cells to Healthy Phenotypes
Current Medicinal Chemistry Bioinformatics Approaches to Profile the Tumor Microenvironment for Immunotherapeutic Discovery
Current Pharmaceutical Design Polynucleotide Kinase as a Potential Target for Enhancing Cytotoxicity by Ionizing Radiation and Topoisomerase I Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Fractal Analysis of the Bone Marrow in Myelodysplastic Syndromes
Current Bioinformatics Telomeres, Senescence and Longevity: The Role of Oxidative Stress and Antioxidants
Current Pharmacogenomics Green Tea Catechins as Novel Antitumor and Antiangiogenic Compounds
Current Medicinal Chemistry - Anti-Cancer Agents Molecular Targeting of Breast Cancer: Molecular Imaging and Therapy
Current Pharmaceutical Biotechnology Current Molecularly Targeting Therapies in NSCLC and Melanoma
Anti-Cancer Agents in Medicinal Chemistry Role of microRNA Deregulation in Breast Cancer Cell Chemoresistance and Stemness
Current Medicinal Chemistry Myc - What We have Learned from Flies
Current Drug Targets AAVs Anatomy: Roadmap for Optimizing Vectors for Translational Success
Current Gene Therapy γ-Tocotrienol Induces Apoptosis in Human T Cell Lymphoma through Activation of Both Intrinsic and Extrinsic Pathways
Current Pharmaceutical Design Isovitexin Inhibits Stemness and Induces Apoptosis in Hepatocellular Carcinoma SK-Hep-1 Spheroids by Upregulating miR-34a Expression
Anti-Cancer Agents in Medicinal Chemistry Obesity: Current Treatment and Future Horizons
Mini-Reviews in Medicinal Chemistry